HAMILTON, N.J., March 22, 2011 /PRNewswire/ -- VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today that it will be exhibiting at the 17th SBS Annual Conference & Exhibition at the Gaylord Palms Resort and Convention Center in Orlando, Florida, March 27-31, 2011. VENENUM Biodesign will be exhibiting at booth #524.
VENENUM Biodesign was established with the mission to improve patients' lives through the discovery of new therapeutic compounds. They are committed to building platforms for drug discovery research from novel targets to preclinical implementation. VENENUM Biodesign, a company within the Genesis Biotechnology Group, is located in "Einstein's Alley," the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible to other academic medical centers, biotech, and pharmaceutical companies in the New York, New Jersey, and Pennsylvania area.
This new facility is a unique blend of upscale office space with state-of-the-art laboratory facilities designed with a specialized floor plan to accommodate the Biodesign Compound Collection, which includes 5.5 million proprietary compounds (the "ECLiPS" collection), six newly designed VENENUM Targeted Libraries (VTLs), and approximately 80,000 compounds from commercial sources. This small molecule collection is one of the largest in the world and, combined with state-of-the-art UHTS capabilities, is a powerful tool to generate quality platforms for drug discovery.
There are expansive laboratories to accommodate mammalian and yeast cell culture, siRNA technology, protein engineering and production, cellular reagent generation, structural biology, and in vitro assay and in vivo model development. VENENUM Biodesign's new facility has been engineered to specifically accommodate their well-published and experienced Target Biology department, which identifies and validates novel targets. They are currently completing additional laboratory space immediately adjacent to the Target Biology Division to accommodate a growing Medicinal Chemistry team which implements and executes Hit-to-Lead and Lead Optimization programs.
According to Dr. Maria Webb, Chief Scientific Officer (CSO), "VENENUM is well-positioned with full ranging 'Gene to Lead' capabilities in early drug discovery to partner with pharma and non-profits. We are actively seeking those collaborations. VENENUM is also working to identify hits against novel targets and advance these through our Medicinal Chemistry."
To find out more, please visit http://www.venenumbiodesign.com.
|SOURCE VENENUM Biodesign|
Copyright©2010 PR Newswire.
All rights reserved